Alumis shares climb after its psoriasis drug met all late-stage trial goals, showing strong skin clearance, fast results, and favorable safety, while beating a rival treatment.
Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and visceral fat from two experimental obesity drugs, with more results expected in 2026.
RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing GLP-1 treatment side effects and potential FDA approval paths.